EW vs ZTS

Edwards Lifesciences (EW) trades near its 52-week high at $86.30, reflecting strong recent price momentum (+30.4% 1Y, +18.3% 1M), supported by consistent revenue growth of 14.7% YoY and a solid track record of earnings beats over the past four quarters (avg. surprise: 9.24%). The company exhibits best-in-class profitability with a 78.2% gross margin and 27.4% operating margin, significantly above sector averages, while maintaining a fortress balance sheet with a Debt/Equity ratio of just 0.07 and a Current Ratio of 4.0. However, near-term earnings growth is deeply negative (-90.3% YoY), creating a dislocation between top-line strength and bottom-line performance, and insider selling worth $4.7M over the last six months raises caution. While analysts maintain a 'buy' recommendation with a $93.94 target implying 8.9% upside, valuation appears stretched relative to growth, particularly when compared to higher-growth peers like BNTX or capital-efficient leaders like ZTS.

Zoetis Inc. (ZTS) presents a compelling investment opportunity despite near-term price underperformance, with shares down 29.9% over the past year. The company demonstrates exceptional profitability, including a 39.33% operating margin and 49.87% ROE—both materially above sector averages—while maintaining consistent earnings growth and a strong track record of beating estimates in 3 of the last 4 quarters. Valuation remains attractive relative to peers, trading at a forward P/E of 19.06 versus the sector average of 43.86, creating significant margin of safety. Analysts reflect this optimism with a $170.63 target price, implying ~41% upside, supported by durable cash flows and a disciplined capital allocation strategy including a sustainable 1.66% dividend yield.